



Angiochem to Present at ASCO 2016

MONTREAL, QC--(Marketwired - May 18, 2016) -Angiochem, a biotechnology company developing peptide-drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make an oral presentation during the “Central Nervous System Tumors” session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7, 2016. Angiochem’s presentation will take place June 5th.

“We are honoured to have been chosen to present at ASCO 2016,” said John Huss, Executive Chairman of Angiochem. “We look forward to this premiere conference where oncology professionals from around the world meet to present ground-breaking cancer research.”

Angiochem is focused on developing ANG1005 for the treatment of Leptomeningeal Carcinomatosis in patients with breast cancer and brain metastases. It recently announced a scheduled End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss clinical study results of the compound and plans for Phase 3.

Date: June 5
Time: 9:12
Location: S100a
Presenter: Dr. Priya Kumthekar
Abstract #: 2004

About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the

BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.

Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit <http://www.angiochem.com>.

For more information, please contact:

Mr. John Huss
Executive Chairman
514-591-7991
jhuss@angiochem.com

Crystal Quast
Bullseye Corporate
647-529-6364
Quast@BullseyeCorporate.com